SG Americas Securities LLC Sells 55,996 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 96.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,862 shares of the medical research company’s stock after selling 55,996 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $529,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Charles River Laboratories International by 15.8% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 703 shares of the medical research company’s stock worth $265,000 after purchasing an additional 96 shares in the last quarter. Strs Ohio grew its holdings in shares of Charles River Laboratories International by 11.5% during the first quarter. Strs Ohio now owns 151,994 shares of the medical research company’s stock worth $43,161,000 after purchasing an additional 15,702 shares in the last quarter. Avitas Wealth Management LLC purchased a new position in shares of Charles River Laboratories International during the first quarter worth about $344,000. Central Bank & Trust Co. grew its holdings in shares of Charles River Laboratories International by 243.4% during the first quarter. Central Bank & Trust Co. now owns 17,613 shares of the medical research company’s stock worth $5,001,000 after purchasing an additional 12,484 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC grew its holdings in shares of Charles River Laboratories International by 67.8% during the fourth quarter. Intercontinental Wealth Advisors LLC now owns 2,446 shares of the medical research company’s stock worth $922,000 after purchasing an additional 988 shares in the last quarter. 93.06% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $227.64 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.12 and a current ratio of 1.34. Charles River Laboratories International, Inc. has a fifty-two week low of $203.37 and a fifty-two week high of $460.21. The stock has a 50 day moving average price of $226.50 and a two-hundred day moving average price of $262.75. The company has a market capitalization of $11.57 billion, a P/E ratio of 27.73, a PEG ratio of 1.51 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last announced its earnings results on Wednesday, August 3rd. The medical research company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.03. The company had revenue of $973.13 million during the quarter, compared to the consensus estimate of $995.12 million. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.61 earnings per share. Analysts expect that Charles River Laboratories International, Inc. will post 11.5 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Guggenheim assumed coverage on Charles River Laboratories International in a report on Monday, May 23rd. They set a “neutral” rating for the company. They noted that the move was a valuation call. KeyCorp cut their price objective on Charles River Laboratories International from $390.00 to $300.00 in a report on Thursday, May 5th. Morgan Stanley lowered Charles River Laboratories International from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $350.00 to $250.00 in a research note on Thursday. Deutsche Bank Aktiengesellschaft cut their target price on Charles River Laboratories International from $350.00 to $290.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. Finally, Stephens set a $315.00 target price on Charles River Laboratories International in a research note on Monday, June 20th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $361.00.

Insider Activity at Charles River Laboratories International

In related news, Director George Massaro sold 178 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. Following the completion of the transaction, the director now owns 4,677 shares in the company, valued at $1,080,199.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.10% of the stock is owned by corporate insiders.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.